Akanda Corp. (AKAN) AI Stock Analysis
AKAN AI stock analysis summary
AI ResearchAkanda Corp. (AKAN) is a UK-headquartered company cultivating and distributing cannabis-based medical and wellness products. In FY2025, revenue fell 69.2% to $258,075 while net loss expanded to -$45.7M. As of June 30, 2026, the company holds negative shareholders' equity of -$15.2M and net debt of $17.8M.
- Market cap
- $3.2M
- Revenue (TTM)
- $662,469
- P/E
- —
- 1Y return
- -97.6% S&P 500 16.8%
- Avg. target
- —
Bull case
- Akanda Corp. generated a 5-year revenue CAGR of 162.7% from FY2020 to FY2025.
- Quarterly revenue increased by 21.9% year-over-year for the period ending June 30, 2026.
- Trailing twelve-month revenue improved to $662,469 relative to the FY2025 full-year level of $258,075.
Bear case
- The company posted a substantial net loss of -$45.7M in FY2025 alongside an operating margin of -1931.0%.
- Balance sheet health is weak, marked by negative shareholders' equity of -$15.2M and a low current ratio of 0.22 as of June 30, 2026.
- The stock experienced severe depreciation, falling 97.6% over the trailing 1-year period while the S&P 500 gained 16.8%.
What Akanda does
Akanda Corp., operating through its subsidiaries, focuses on cultivating, manufacturing, and distributing cannabis products across the United Kingdom, Lesotho, and globally. Specializing in the production of cannabis-based medical and wellness products, the company aims to meet the growing demand for therapeutic cannabis solutions. Founded in 2021 and headquartered in New Romney, United Kingdom, Akanda Corp. seeks to expand its presence in the international cannabis market through comprehensive cultivation practices, state-of-the-art manufacturing facilities, and expansive distribution networks to supply sustainable products for medical and wellness needs.
Growth and profitability
Akanda Corp. generated revenue of $41,431 in FY2021, which climbed to $2.6M in FY2022 before dropping to $2.2M in FY2023, $836,664 in FY2024, and $258,075 in FY2025. Across FY2025, revenue fell 69.2%, while gross margin deteriorated to -60.5% and operating margin reached -1931.0%. Net loss widened from -$4.1M in FY2024 to -$45.7M in FY2025, reflecting a net margin of -17690.2%. For the trailing twelve months ended June 30, 2026, revenue stood at $662,469 with an operating margin of -1191.5% and an eps of -$14935.32, although quarterly revenue growth year-over-year reached 21.9%.
Balance sheet and cash flow
As of June 30, 2026, Akanda Corp. held cash and short-term investments of $755,238 against total debt of $18.6M, resulting in net debt of $17.8M. Total assets stood at $6.4M, with a current ratio of 0.22 and negative shareholders' equity of -$15.2M. Cash flow remained constrained, as FY2025 operating cash flow was -$6.7M and free cash flow was -$8.0M after capital expenditures of $1.2M.
Valuation and performance
Akanda Corp. closed at $1.20 on October 16, 2026, giving it a market capitalization of $3.2M and an enterprise value of $15.4M. Its price-to-sales ratio of 4.8x sits above the 4.1x median of its US-listed Healthcare peers, while its enterprise value-to-revenue ratio is 59.7x. Over the past year, the stock recorded a 1-year return of -97.6%, lagging the S&P 500 (SPY) return of 16.8%. The shares trade -86.5% relative to their 200-day average and sit near their 52-week low of $1.17.
What analysts expect
Akanda Corp. recorded 0 EPS beats over the last 4 quarters, reflecting consistent earnings misses against expectations. The stock lacks published Wall Street analyst ratings, consensus earnings estimates, and price targets. With a market capitalization of $3.2M and beta of 14.19, the shares exhibit extreme price swings, having traded between a 52-week low of $1.17 and a 52-week high of $78.90.
Key risks and what to watch
- A thin cash buffer of $755,238 against total debt of $18.6M creates significant liquidity and refinancing risks.
- Operating cash flow was -$6.7M and free cash flow was -$8.0M in FY2025, indicating ongoing operational cash burn.
- Extreme share price volatility is highlighted by a beta of 14.19 and a drop from a 52-week high of $78.90 to a low of $1.17.
- The business recorded 0 EPS beats over the last 4 quarters, pointing to persistent financial underperformance.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this AKAN AI stock analysis
This page is an AI-written research summary of Akanda Corp. (AKAN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: AKAN income statement, AKAN balance sheet, AKAN key metrics, AKAN chart. See the AKAN stock overview for the latest quote and news.
AKAN AI stock analysis FAQ
What does Akanda Corp. do?
Akanda Corp. is a healthcare company that cultivates, manufactures, and distributes cannabis-based medical and wellness products across the United Kingdom, Lesotho, and international markets.
What is Akanda Corp.'s current financial position?
As of June 30, 2026, Akanda Corp. held $755,238 in cash and short-term investments, $18.6M in total debt, and negative shareholders' equity of -$15.2M, with a current ratio of 0.22.
Does Akanda Corp. pay a dividend?
Akanda Corp. does not pay a dividend, as the company operates at a net loss of -$45.7M in FY2025 and requires capital to fund operations.
What was Akanda Corp.'s stock performance over the past year?
Akanda Corp. recorded a 1-year return of -97.6% as of October 16, 2026, underperforming the S&P 500 (SPY), which returned 16.8% over the same timeframe.
Who owns Akanda Corp. stock?
Insiders own 0.6% of Akanda Corp., while institutional investors hold 0.1%, and short interest represents 8.5% of the float.